Abivax (NASDAQ:ABVX) Given “Market Outperform” Rating at Citizens Jmp

Abivax (NASDAQ:ABVX)‘s stock had its “market outperform” rating reissued by analysts at Citizens Jmp in a note issued to investors on Tuesday,Benzinga reports. They presently have a $131.00 price objective on the stock. Citizens Jmp’s price target would suggest a potential upside of 3.38% from the stock’s previous close.

ABVX has been the topic of a number of other research reports. Wedbush started coverage on Abivax in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $110.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Abivax in a research report on Monday, April 20th. Wall Street Zen raised Abivax from a “sell” rating to a “hold” rating in a research note on Saturday. BTIG Research reiterated a “buy” rating and issued a $150.00 price objective on shares of Abivax in a report on Wednesday, February 25th. Finally, Barclays increased their target price on Abivax from $142.00 to $148.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 24th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $137.15.

Abivax Price Performance

Shares of ABVX stock opened at $126.72 on Tuesday. Abivax has a 1-year low of $5.62 and a 1-year high of $148.83. The firm has a market cap of $10.10 billion, a PE ratio of -24.32 and a beta of 0.84. The company has a 50-day moving average of $117.84 and a two-hundred day moving average of $119.29.

Abivax (NASDAQ:ABVX) last released its quarterly earnings results on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The company had revenue of $1.56 million during the quarter, compared to analysts’ expectations of $0.40 million. Sell-side analysts anticipate that Abivax will post -3.84 EPS for the current fiscal year.

Institutional Investors Weigh In On Abivax

A number of hedge funds have recently added to or reduced their stakes in the business. Jefferies Financial Group Inc. acquired a new stake in shares of Abivax in the third quarter valued at $38,827,000. Federated Hermes Inc. acquired a new position in Abivax during the 3rd quarter worth $8,448,000. Persistent Asset Partners Ltd purchased a new stake in Abivax during the 3rd quarter worth about $815,000. Atika Capital Management LLC purchased a new stake in Abivax during the 3rd quarter worth about $5,858,000. Finally, Nan Fung Trinity HK Ltd. raised its position in Abivax by 11.8% in the 4th quarter. Nan Fung Trinity HK Ltd. now owns 113,365 shares of the company’s stock valued at $15,288,000 after purchasing an additional 12,000 shares in the last quarter. 47.91% of the stock is currently owned by institutional investors and hedge funds.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.